The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
about
Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetesSodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsSodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A ReviewProtein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and ureaMesenchymal Stem Cells as Therapeutic Candidates for Halting the Progression of Diabetic NephropathySodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease.Sodium Glucose Cotransporter 2 (SGLT2) Plays as a Physiological Glucose Sensor and Regulates Cellular Contractility in Rat Mesangial Cells.Renoprotective effects of combined SGLT2 and ACE inhibitor therapy in diabetic Dahl S rats.Piwil 2 gene transfection changes the autophagy status in a rat model of diabetic nephropathy.Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an updateRationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.The effects of dual PPARα/γ agonism compared with ACE inhibition in the BTBRob/ob mouse model of diabetes and diabetic nephropathy.Diabetic nephropathy: landmark clinical trials and tribulations.Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective?Recent advances in glucose-lowering treatment to reduce diabetic kidney disease.Extra-glycaemic properties of empagliflozin.A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans.The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats.SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy.Developing Treatments for Chronic Kidney Disease in the 21st Century.Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus.Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects.The next generation of therapeutics for chronic kidney diseaseTargeting inflammation in diabetic kidney disease: early clinical trials.Accumulation of worn-out GBM material substantially contributes to mesangial matrix expansion in diabetic nephropathy.SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE.Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.Renal Effects of SGLT-2 Inhibitors and Other Anti-diabetic Drugs: Clinical Relevance and Potential Risks.The effect of dapagliflozin on renal function in patients with type 2 diabetes.Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease.Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome.Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.Carnosine Attenuates the Development of both Type 2 Diabetes and Diabetic Nephropathy in BTBR ob/ob Mice.Effect of Dapagliflozin Treatment on Fluid and Electrolyte Balance in Diabetic Rats.Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes.Expression profiling and immunolocalization of Na+-D-glucose-cotransporter 1 in mice employing knockout mice as specificity control indicate novel locations and differences between mice and rats.Novel avenues for drug discovery in diabetic kidney disease.Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus.Modelling diabetic nephropathy in mice.
P2860
Q26777994-ECD7EC7E-EAAD-438F-9366-57F195E9554AQ26864336-9C895967-5071-46D6-A6BA-6E3748286331Q28072765-01C6DC91-3DEC-435E-9AED-A697C7517044Q28079134-DEC0FEDE-00DE-4BD6-98C9-7FFD43D5C57DQ28085593-07AFD3C3-E3E1-491D-82E0-0C4BF24D9B82Q28354224-343C126F-B8DC-4761-832E-DC6D14CD140CQ35887931-79A14B2B-C70A-4AB5-9C51-72FBA395C22AQ35964702-EB248745-2E36-49FB-9973-31173C977712Q36004330-359A5760-6B4A-40E2-91BE-CE013E6DB078Q36261516-48C16B17-9CD1-45CB-8631-8E1ED6A0F95AQ36435496-81C6C959-D393-4682-A6B3-7E712D748B90Q36765350-BEA93B84-EA8E-4C6C-A420-3BBD42E2F6A2Q37699675-BB75621D-6281-4C39-8870-3EA035554DDAQ38338539-570DA492-180A-4563-95EE-ED3F8EA1E02BQ38429845-96CA51F0-B4BC-452A-9681-1F656D9C0F74Q38442040-16D9DA8E-B083-4597-A3A9-676712F7624EQ38494441-C109837A-3DEB-4757-B276-B3E0D52D3295Q38537119-C7ED035C-2AAA-4224-954E-7B3DA418C780Q38698841-94827ABD-C65B-49B1-9BA8-42E40EF2E6ACQ38775305-8CC41EEC-E664-4E53-9198-72A04A72D0DEQ38781550-84A24F2E-413E-4FCF-8F8F-DBD766CDB9FEQ38783130-D771280D-DCF4-4686-95B7-0814D8E4C6C8Q38800979-04313236-BD67-48CE-9839-119E08B02EBAQ38845590-01B55E33-BCBD-442F-975A-D5131F03BD7CQ38857166-A7A508E3-20C6-4B09-A91D-14FDC4E311E6Q38947594-AE9F2E49-2DF7-4A8D-A697-05FF3FC8D758Q38961637-E784E7D0-F413-4421-8C02-B64D0404213FQ39017610-31CCD0B3-1777-4906-9929-6BECEE8E524FQ39290337-0EA7762B-8683-4750-9B67-446D8721D0CDQ39984210-FFB6FA7E-2AB2-4EC0-BA5D-B1B1B59A4CB0Q41814998-AD39E36A-D64B-443E-9E51-547D426E156DQ41849079-89DAF315-784A-4101-BCF9-DED62D4BDD3FQ42006157-7687A19E-3270-4169-880E-0698E1BDBB04Q42035564-8292701F-E8C5-44A2-82D3-F18A6C8AA6D7Q42763621-A945131A-6B06-4444-95F8-EAA24E293D5BQ46320593-84623F71-401B-4E6A-8D67-4E1F77B89C1FQ47164947-79F7C159-63DA-4DDA-BEDA-07BEF37AECE7Q47395215-1F8E21F0-53C3-42DB-84E7-1D9CA41E49BEQ47700645-AC945A74-DC2A-48EC-A1A0-2FBFF5588890Q47735079-44296B6A-03E6-443D-9E1C-E3B1A5628DA9
P2860
The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
The SGLT2 inhibitor empagliflo ...... with and without hypertension.
@en
type
label
The SGLT2 inhibitor empagliflo ...... with and without hypertension.
@en
prefLabel
The SGLT2 inhibitor empagliflo ...... with and without hypertension.
@en
P2093
P2860
P1476
The SGLT2 inhibitor empagliflo ...... with and without hypertension.
@en
P2093
Bernd Hohenstein
Christian Hugo
Christoph Bartaun
Eric Mayoux
Natalia Jarzebska
P2860
P304
P356
10.1152/AJPRENAL.00145.2014
P577
2014-06-18T00:00:00Z